EUDA Health Holdings Ltd Stock Price, News & Analysis

EUDA Health Holdings (NASDAQ: EUDA) announced an amendment to its warrant agreement with Streeterville Capital dated December 4, 2025. The amendment reduces the Warrant exercise price from $6.00 to $4.00 and lowers the minimum closing price that triggers a Forced Exercise from $7.50 to $6.00. The original Warrant was issued for an aggregate purchase price of $100,000 and is exercisable into up to 2,000,000 ordinary shares. The Cash Exercise Period is ninety (90) days from issuance, after which Streeterville will be deemed to have made a cashless exercise at a 1-for-10 conversion if not exercised for cash.

EUDA (NASDAQ: EUDA) announced on December 30, 2025 the launch of a nationwide stem cell extraction, cryostorage and clinical delivery platform in China in partnership with Shenzhen Inno Immune and Wuhan Kaien Hospital. The platform combines centralized processing with decentralized clinical access, cold-chain logistics and integration into longevity medicine.

Key infrastructure includes an initial ~50,000 patient-unit cryogenic hub in Shenzhen and a planned ~200,000 patient-unit capacity at Wuhan Kaien, plus a partner network of extraction clinics and regulated transport for sample movement and clinical delivery.

EUDA Health (NASDAQ: EUDA) will launch EUDA Helixé 2.0 in January 2026 as an upgraded premium vitality and longevity supplement.

Key changes include a 20% increase in New Zealand deer placenta powder (from 100 mg to 120 mg), replacement of L-glutathione with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent), advanced preservation and delivery methods (freeze drying, refining, nitrogen encapsulation, and nano emulsification replacing enteric coating), a new proprietary bottle design, and New Zealand Halal certification to enable broader Muslim-market distribution.

EUDA (NASDAQ: EUDA) launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen on Dec 23, 2025, accelerating its regenerative-medicine strategy.

The company is upgrading Shenzhen Inno’s cGMP facility into a production and innovation center integrating GO POSB’s iPSC platform and technologies from two Japanese partners to support iPSC expansion, stem cell preparation and T-cell immunotherapies. EUDA also holds distribution rights for Shenzhen Inno’s T-cell immunotherapies and stated an intention to acquire GO POSB. The Shenzhen clinic will offer advanced cell therapies, AI-guided life-cycle management, and integrated Eastern/Western/functional medicine.

EUDA Health Holdings (NASDAQ: EUDA) announced on December 22, 2025 a technology integration that adds the QB utility token into its digital health and rewards platform.

Customers and agents can earn and redeem QB tokens for EUDA offerings including Bioenergy Capsule treatments, Euda Helixe supplements, and selected stem cell services. EUDA will receive QB tokens solely in exchange for products and services, recorded as non-monetary, product-based transactions.

The QB token is built on Binance Smart Chain and interoperates with the USD1 stablecoin (1:1 redeemable for US dollar) using Chainlink CCIP; QB Limited is the token issuer and exclusive distributor of Euda Helixe in Hong Kong and Macau.

EUDA Health Holdings (NASDAQ: EUDA) announced plans to integrate a third‑party utility cryptocurrency called QB into its digital health and rewards platform, with QB scheduled for launch in January 2026. The token will be usable across EUDA’s ecosystem for payments, rewards, and access to healthcare products and partner services in Singapore, Malaysia, and China. EUDA also plans to hold QB in its digital asset treasury to support long‑term financial flexibility and participation in blockchain initiatives. The initiative aims to link healthcare engagement with decentralized finance to enhance loyalty, access, and community participation.

EUDA Health Holdings (NASDAQ: EUDA) announced it entered a securities purchase agreement dated November 26, 2025 to sell a convertible warrant to Streeterville Capital for an aggregate purchase price of US$100,000. The Warrant is exercisable into up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share and was offered under the company’s Form F-3 shelf registration (File No. 333-282723) with a related prospectus supplement.

The Warrant allows cash-only exercise for 90 days from issuance (subject to extension). The company may require partial forced exercise up to 10% of cumulative dollar trading volume if the share price is ≥ US$7.50 for five consecutive trading days and trading volume in that period is at least US$1,500,000. Management described the financing as flexibility to support expansion across Singapore, Malaysia and China.

EUDA (NASDAQ: EUDA) announced on October 23, 2025 that its wholly owned subsidiary CK Health Plus will expand into India via a master license and representative partnership with SafeRock India.

The agreement aims to deploy CK Health Plus’ Bioenergy Capsule Therapies and EUDA Helixé supplements across major Indian cities including Mumbai and Bangalore, leveraging SafeRock India’s systems integration capabilities and nationwide network to roll out a network-marketing wellness ecosystem.

EUDA Health Holdings (NASDAQ: EUDA) announced on October 20, 2025 that its wholly owned subsidiary CK Health Plus received a Malaysian Direct Selling License (AJL 932509) from the Ministry of Domestic Trade and Cost of Living.

The License authorizes nationwide direct selling and multi-level marketing activities, including member recruitment, distribution of EUDA Helixé supplements, and operation of Bioenergy Capsule Centers. CK Health Plus said it will roll out centers and expand its agent network across Malaysia and strengthen synergies with Singapore operations while providing product training to agents to ensure ethical wellness education.